These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 9143415)
1. Serum levels of C-erbB-2 (HER-2/neu) in patients with malignant and non-malignant diseases. Molina R; Jo J; Filella X; Bruix J; Castells A; Hague M; Ballesta AM Tumour Biol; 1997; 18(3):188-96. PubMed ID: 9143415 [TBL] [Abstract][Full Text] [Related]
2. c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value. Molina R; Jo J; Filella X; Zanon G; Pahisa J; Mu noz M; Farrus B; Latre ML; Escriche C; Estape J; Ballesta AM Breast Cancer Res Treat; 1998 Sep; 51(2):109-19. PubMed ID: 9879773 [TBL] [Abstract][Full Text] [Related]
3. C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis. Molina R; Jo J; Filella X; Zanon G; Pahisa J; Muñoz M; Farrus B; Latre ML; Gimenez N; Hage M; Estape J; Ballesta AM Anticancer Res; 1996; 16(4B):2295-300. PubMed ID: 8694559 [TBL] [Abstract][Full Text] [Related]
4. Study of a new tumor marker, CYFRA 21-1, in malignant and nonmalignant diseases. Molina R; Agusti C; Filella X; Jo J; Joseph J; Giménez N; Ballesta AM Tumour Biol; 1994; 15(6):318-25. PubMed ID: 7997803 [TBL] [Abstract][Full Text] [Related]
5. Circulating levels of HER-2/neu oncoprotein in breast cancer. Molina R; Escudero JM; Muñoz M; Augé JM; Filella X Clin Chem Lab Med; 2012 Jan; 50(1):5-21. PubMed ID: 22505536 [TBL] [Abstract][Full Text] [Related]
6. C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patients. Molina R; Jo J; Filella X; Zanón G; Farrus B; Muñoz M; Latre ML; Pahisa J; Velasco M; Fernandez P; Estapé J; Ballesta AM Anticancer Res; 1999; 19(4A):2551-5. PubMed ID: 10470193 [TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of serum c-erbB-2 protein in breast cancer patients. Willsher PC; Beaver J; Pinder S; Bell JA; Ellis IO; Blamey RW; Robertson JF Breast Cancer Res Treat; 1996; 40(3):251-5. PubMed ID: 8883967 [TBL] [Abstract][Full Text] [Related]
8. Measurement of c-erbB-2 proteins in sera from patients with carcinomas and in breast tumor tissue cytosols: correlation with serum tumor markers and membrane-bound oncoprotein. Wu JT; Astill ME; Gagon SD; Bryson L J Clin Lab Anal; 1995; 9(3):151-65. PubMed ID: 7541455 [TBL] [Abstract][Full Text] [Related]
9. Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3. Molina R; Jo J; Zanón G; Filella X; Farrus B; Muñoz M; Latre ML; Pahisa J; Velasco M; Fernandez P; Estapé J; Ballesta AM Br J Cancer; 1996 Oct; 74(7):1126-31. PubMed ID: 8855986 [TBL] [Abstract][Full Text] [Related]
10. c-erbB-2 protein in serum of primary lung cancer patients. Filiberti R; Marroni P; Paganuzzi M; Izzo V; Padovani P; Cafferata M; Ardizzoni A; Neri M; Raimondi L; Puntoni R Cancer Detect Prev; 2002; 26(1):64-8. PubMed ID: 12088205 [TBL] [Abstract][Full Text] [Related]
11. Serum c-erbB-2 protein in breast cancer patients. Chearskul S; Sinlarat P; Bhothisuwan K; Churintrapun M; Ornrhebroi S; Klinsala N; Sungkabunchoo S J Med Assoc Thai; 2000 Aug; 83(8):886-93. PubMed ID: 10998842 [TBL] [Abstract][Full Text] [Related]
12. Clinical significance and prognostic value of serum sHER-2/neu levels in patients with solid tumors. Papila C; Uzun H; Balci H; Zerdali H; Sezgin C; Can G; Yanardag H Med Oncol; 2009; 26(2):151-6. PubMed ID: 18855148 [TBL] [Abstract][Full Text] [Related]
13. Serum levels of c-erbb-2 correlate with advanced stage and liver metastasis in colorectal cancer. Polychronidis AC; Tsaroucha AK; Anagnostoulis SK; Efstathiou EE; Georgiadis PG; Simopoulos CE Folia Med (Plovdiv); 2003; 45(2):12-6. PubMed ID: 12943051 [TBL] [Abstract][Full Text] [Related]
14. Serum c-erbB-2 protein is a useful marker for monitoring tumor recurrence of the breast. Imoto S; Wada N; Hasebe T; Ochiai A; Kitoh T Int J Cancer; 2007 Jan; 120(2):357-61. PubMed ID: 17044019 [TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of soluble c-erbB-2 for patients with metastatic breast cancer predicting the response to second-line hormone or chemotherapy. Classen S; Kopp R; Possinger K; Weidenhagen R; Eiermann W; Wilmanns W Tumour Biol; 2002; 23(2):70-5. PubMed ID: 12065844 [TBL] [Abstract][Full Text] [Related]
16. The presence of soluble c-erbB-2 in saliva and serum among women with breast carcinoma: a preliminary study. Streckfus C; Bigler L; Dellinger T; Dai X; Kingman A; Thigpen JT Clin Cancer Res; 2000 Jun; 6(6):2363-70. PubMed ID: 10873088 [TBL] [Abstract][Full Text] [Related]
17. Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer. Isola JJ; Holli K; Oksa H; Teramoto Y; Kallioniemi OP Cancer; 1994 Feb; 73(3):652-8. PubMed ID: 7905363 [TBL] [Abstract][Full Text] [Related]
18. Tissue and serum c-erbB-2 and tissue EGFR in breast carcinoma: three years follow-up. Mansour OA; Zekri AR; Harvey J; Teramoto Y; el-Ahmady O Anticancer Res; 1997; 17(4B):3101-6. PubMed ID: 9329611 [TBL] [Abstract][Full Text] [Related]
19. Serum levels of c-erbB-2 protein in digestive diseases. Motoo Y; Sawabu N; Yamaguchi Y; Mouri I; Yamakawa O; Watanabe H; Ohta H; Okai T; Makino H J Gastroenterol; 1994 Oct; 29(5):616-20. PubMed ID: 7528080 [TBL] [Abstract][Full Text] [Related]
20. Clinical utility of serum HER-2/neu testing on the Bayer Immuno 1 automated system in breast cancer. Cook GB; Neaman IE; Goldblatt JL; Cambetas DR; Hussain M; Lüftner D; Yeung KK; Chan DW; Schwartz MK; Allard WJ Anticancer Res; 2001; 21(2B):1465-70. PubMed ID: 11396233 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]